| Primary | Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12) | SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ) at 12 weeks after stopping study treatment. | Full Analysis Set: all enrolled participants who took at least 1 dose of the study drug | Posted | | Number | 95% Confidence Interval | percentage of participants | | Posttreatment Week 12 | | | | ID | Title | Description |
|---|
| OG000 | SOF/VEL | SOF/VEL (400/100 mg) FDC tablet orally once daily for 12 weeks in participants with chronic HCV infection who received a liver transplant |
| | | Title | Denominators | Categories |
|---|
| | |
| |
| Primary | Percentage of Participants Who Prematurely Discontinued Study Drug Due to Any Adverse Event | | Safety Analysis Set: participants who took at least 1 dose if the study drug. | Posted | | Number | | percentage of participants | | Up to 12 weeks | | | | ID | Title | Description |
|---|
| OG000 | SOF/VEL | SOF/VEL (400/100 mg) FDC tablet orally once daily for 12 weeks in participants with chronic HCV infection who received a liver transplant |
| | |
| Secondary | Percentage of Participants With Sustained Virologic Response 4 Weeks After Cessation of Therapy (SVR4) | SVR4 was defined as HCV RNA < LLOQ at 4 weeks after stopping study treatment. | | Posted | | Number | 95% Confidence Interval | Percentage of participants | | Posttreatment Week 4 | | | | ID | Title | Description |
|---|
| OG000 | SOF/VEL | SOF/VEL (400/100 mg) FDC tablet orally once daily for 12 weeks in participants with chronic HCV infection who received a liver transplant |
| | |
| Secondary | Percentage of Participants With HCV RNA < LLOQ at Week 2 | | | Posted | | Number | 95% Confidence Interval | percentage of participants | | Week 2 | | | | ID | Title | Description |
|---|
| OG000 | SOF/VEL | SOF/VEL (400/100 mg) FDC tablet orally once daily for 12 weeks in participants with chronic HCV infection who received a liver transplant |
| | |
| Secondary | Percentage of Participants With HCV RNA < LLOQ at Week 4 | | Participants in the Full Analysis Set with available data were analyzed. | Posted | | Number | 95% Confidence Interval | percentage of participants | | Week 4 | | | | ID | Title | Description |
|---|
| OG000 | SOF/VEL | SOF/VEL (400/100 mg) FDC tablet orally once daily for 12 weeks in participants with chronic HCV infection who received a liver transplant |
| | |
| Secondary | Percentage of Participants With HCV RNA < LLOQ at Week 8 | | Participants in the Full Analysis Set with available data were analyzed. | Posted | | Number | 95% Confidence Interval | percentage of participants | | Week 8 | | | | ID | Title | Description |
|---|
| OG000 | SOF/VEL | SOF/VEL (400/100 mg) FDC tablet orally once daily for 12 weeks in participants with chronic HCV infection who received a liver transplant |
| | |
| Secondary | Percentage of Participants With HCV RNA < LLOQ at Week 12 | | Participants in the Full Analysis Set with available data were analyzed. | Posted | | Number | 95% Confidence Interval | percentage of participants | | Week 12 | | | | ID | Title | Description |
|---|
| OG000 | SOF/VEL | SOF/VEL (400/100 mg) FDC tablet orally once daily for 12 weeks in participants with chronic HCV infection who received a liver transplant |
| | |
| Secondary | HCV RNA at Week 2 | | Participants in the Full Analysis Set with available data were analyzed. | Posted | | Mean | Standard Deviation | log10 IU/mL | | Week 2 | | | | ID | Title | Description |
|---|
| OG000 | SOF/VEL | SOF/VEL (400/100 mg) FDC tablet orally once daily for 12 weeks in participants with chronic HCV infection who received a liver transplant |
| | |
| Secondary | HCV RNA at Week 4 | | Participants in the Full Analysis Set with available data were analyzed. | Posted | | Mean | Standard Deviation | log10 IU/mL | | Week 4 | | | | ID | Title | Description |
|---|
| OG000 | SOF/VEL | SOF/VEL (400/100 mg) FDC tablet orally once daily for 12 weeks in participants with chronic HCV infection who received a liver transplant |
| | |
| Secondary | HCV RNA at Week 8 | | Participants in the Full Analysis Set with available data were analyzed. | Posted | | Mean | Standard Deviation | log10 IU/mL | | Week 8 | | | | ID | Title | Description |
|---|
| OG000 | SOF/VEL | SOF/VEL (400/100 mg) FDC tablet orally once daily for 12 weeks in participants with chronic HCV infection who received a liver transplant |
| | |
| Secondary | HCV RNA at Week 12 | | Participants in the Full Analysis Set with available data were analyzed. | Posted | | Mean | Standard Deviation | log10 IU/mL | | Week 12 | | | | ID | Title | Description |
|---|
| OG000 | SOF/VEL | SOF/VEL (400/100 mg) FDC tablet orally once daily for 12 weeks in participants with chronic HCV infection who received a liver transplant |
| | |
| Secondary | Change From Baseline in HCV RNA at Week 2 | | Participants in the Full Analysis Set with available data were analyzed. | Posted | | Mean | Standard Deviation | log10 IU/mL | | Baseline; Week 2 | | | | ID | Title | Description |
|---|
| OG000 | SOF/VEL | SOF/VEL (400/100 mg) FDC tablet orally once daily for 12 weeks in participants with chronic HCV infection who received a liver transplant |
| | |
| Secondary | Change From Baseline in HCV RNA at Week 4 | | Participants in the Full Analysis Set with available data were analyzed. | Posted | | Mean | Standard Deviation | log10 IU/mL | | Baseline; Week 4 | | | | ID | Title | Description |
|---|
| OG000 | SOF/VEL | SOF/VEL (400/100 mg) FDC tablet orally once daily for 12 weeks in participants with chronic HCV infection who received a liver transplant |
| | |
| Secondary | Change From Baseline in HCV RNA at Week 8 | | Participants in the Full Analysis Set with available data were analyzed. | Posted | | Mean | Standard Deviation | log10 IU/mL | | Baseline; Week 8 | | | | ID | Title | Description |
|---|
| OG000 | SOF/VEL | SOF/VEL (400/100 mg) FDC tablet orally once daily for 12 weeks in participants with chronic HCV infection who received a liver transplant |
| | |
| Secondary | Change From Baseline in HCV RNA at Week 12 | | Participants in the Full Analysis Set with available data were analyzed. | Posted | | Mean | Standard Deviation | log10 IU/mL | | Baseline; Week 12 | | | | ID | Title | Description |
|---|
| OG000 | SOF/VEL | SOF/VEL (400/100 mg) FDC tablet orally once daily for 12 weeks in participants with chronic HCV infection who received a liver transplant |
| | |
| Secondary | Percentage of Participants With Virologic Failure | Virologic failure was defined as On-treatment virologic failure:
- Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA < LLOQ on 2 consecutive measurements while on treatment), or
- Rebound (confirmed > 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or
- Non-response (HCV RNA persistently ≥ LLOQ through 12 weeks of treatment)
Virologic relapse:
- HCV RNA ≥ LLOQ during the post-treatment period having achieved HCV RNA < LLOQ at end of treatment, confirmed with 2 consecutive values or last available post-treatment measurement
| | Posted | | Number | | percentage of participants | | Up to Posttreatment Week 12 | | | | ID | Title | Description |
|---|
| OG000 | SOF/VEL | SOF/VEL (400/100 mg) FDC tablet orally once daily for 12 weeks in participants with chronic HCV infection who received a liver transplant |
| |